Literature DB >> 7541042

Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules.

P S Linsley1, S G Nadler, J Bajorath, R Peach, H T Leung, J Rogers, J Bradshaw, M Stebbins, G Leytze, W Brady.   

Abstract

CD28 and CTLA-4 are homologous T cell receptors of the immunoglobulin (Ig) superfamily, which bind B7 molecules (CD80 and CD86) on antigen-presenting cells and transmit important costimulatory signals during T cell activation. Here we have investigated the subunit structure of CTLA-4 and the stoichiometry of its binding to B7 molecules. We demonstrate CTLA-4 is a homodimer interconnected by one disulfide bond in the extracellular domain at cysteine residue 120. Each monomeric polypeptide chain of CTLA-4 contains a high affinity binding site for B7 molecules; soluble CTLA-4 and CD86 form complexes containing equimolar amounts of monomeric CTLA-4 and CD86 (i.e. a 2:2 molecular complex). Thus, CTLA-4 and probably CD28 have a receptor structure consisting of preexisting covalent homodimers with two binding sites. Dimerization of CTLA-4 and CD28 is not required for B7 binding, nor is it sufficient to trigger signaling.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541042     DOI: 10.1074/jbc.270.25.15417

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.

Authors:  P A van der Merwe; D L Bodian; S Daenke; P Linsley; S J Davis
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

Review 2.  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Authors:  Andrew M Intlekofer; Craig B Thompson
Journal:  J Leukoc Biol       Date:  2013-04-26       Impact factor: 4.962

3.  Structural analysis of natriuretic peptide receptor-C by truncation and site-directed mutagenesis.

Authors:  M Itakura; H Suzuki; S Hirose
Journal:  Biochem J       Date:  1997-03-01       Impact factor: 3.857

4.  Different cell surface oligomeric states of B7-1 and B7-2: implications for signaling.

Authors:  Sumeena Bhatia; Michael Edidin; Steven C Almo; Stanley G Nathenson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-12       Impact factor: 11.205

Review 5.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

6.  Physical instability of a therapeutic Fc fusion protein: domain contributions to conformational and colloidal stability.

Authors:  Jonas L Fast; Amanda A Cordes; John F Carpenter; Theodore W Randolph
Journal:  Biochemistry       Date:  2009-12-15       Impact factor: 3.162

7.  Antitumor immunopreventive effect in mice induced by DNA vaccine encoding a fusion protein of alpha-fetoprotein and CTLA4.

Authors:  Geng Tian; Ji-Lin Yi; Ping Xiong
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

8.  CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

Authors:  Andreas Herrmann; Saul J Priceman; Piotr Swiderski; Maciej Kujawski; Hong Xin; Gregory A Cherryholmes; Wang Zhang; Chunyan Zhang; Christoph Lahtz; Claudia Kowolik; Steve J Forman; Marcin Kortylewski; Hua Yu
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

9.  Evaluation of polymorphism, hypermethylation and expression pattern of CTLA4 gene in a sample of Iranian patients with schizophrenia.

Authors:  Dor Mohammad Kordi-Tamandani; Shahram Vaziri; Nahid Dahmardeh; Adam Torkamanzehi
Journal:  Mol Biol Rep       Date:  2013-05-11       Impact factor: 2.316

10.  PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.

Authors:  Yunlong Zhao; Calvin K Lee; Chia-Hao Lin; Rodrigo B Gassen; Xiaozheng Xu; Zhe Huang; Changchun Xiao; Cristina Bonorino; Li-Fan Lu; Jack D Bui; Enfu Hui
Journal:  Immunity       Date:  2019-11-19       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.